HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF
申请人:Merck Patent GmbH
公开号:US20160096834A1
公开(公告)日:2016-04-07
The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
本发明涉及咪唑吡啶化合物及其药学上可接受的组合物,用作BTK抑制剂。
INHIBITORS OF AKT ACTIVITY
申请人:Zhang Lixin
公开号:US20130116243A1
公开(公告)日:2013-05-09
The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
Ligand cooperativity enables highly enantioselective C–C σ-bond hydroboration of cyclopropanes
作者:Tianhang Wang、Minyan Wang、Yandong Wang、Mingjie Li、Yuan Zheng、Qianwei Chen、Yue Zhao、Zhuangzhi Shi
DOI:10.1016/j.chempr.2022.09.014
日期:2023.1
to high enantioselectivity relies on two distinct ligands that act cooperatively: an exogenous monodentate chiral phosphite that induces enantioselectivity and an endogenous acetylacetonate that exerts a remarkably positive influence on the enhancement of enantioselectivity. Detailed experimental and computational studies elucidate the effect of ligand cooperativity and the key steps involving σ-bond